|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
ABSTRACT |
|---|
|
|
|---|
Cases of paradoxical worsening of opportunistic infections shortly after the beginning of highly active antiretroviral therapy (HAART) prompted questions on the optimal timing of introduction of HAART in patients with inaugural AIDS-related opportunistic infections. We describe three cases of acute respiratory failure after early introduction of HAART in patients treated for Pneumocystis carinii pneumonia (PCP). The three patients had severe PCP that initially improved with anti-PCP and adjunctive steroid therapy. HAART was introduced 1 to 16 d after diagnosis of PCP, and steroids were stopped on Day 15. Seven to 17 d after HAART introduction, the three patients developed a second episode of severe acute respiratory failure with high-grade fever and patchy alveolar opacities on the chest roentgenogram. PCP resistant to cotrimoxazole, pulmonary superinfection, and drug-related pneumonitis were suspected but subsequently ruled out. Bronchoalveolar lavage and lung pathologic findings showed severe nonspecific pulmonary inflammatory foci surrounding a few persistent P. carinii cysts. All three patients recovered after HAART interruption or steroid reintroduction. We conclude that acute respiratory failure can recur after initiation of antiretroviral therapy in patients being treated for severe PCP. This phenomenon could result from rapid pulmonary recruitment of fully competent immune and inflammatory cells responding to a few persistent P. carinii cysts. A short course of steroid therapy may suppress this reaction.
Keywords: parodoxical worsening; HAART; Pneumocystis carinii pneumonia
| |
INTRODUCTION |
|---|
|
|
|---|
Pneumocystis carinii pneumonia (PCP) was rapidly recognized as the most frequent and severe respiratory infection in human immunodeficiency virus (HIV)-infected patients. In the mid-1990s, PCP remained the first manifestation of acquired immunodeficiency syndrome (AIDS) in more than 15% of cases, with a 20% mortality rate at 3 mo despite effective PCP prophylaxis and adjunctive steroid therapy for patients with mild to severe hypoxemia (1). The recent advent of highly active antiretroviral therapy (HAART) has resulted in a marked decrease in the incidence and mortality of opportunistic infections. However, cases of paradoxical worsening of opportunistic infections shortly after the beginning of HAART prompted questions on the optimal timing of introduction of HAART in patients with inaugural AIDS-related opportunistic infections (2). We describe three cases of acute respiratory failure that recurred after early introduction of HAART during treatment of severe PCP.
Case 1
On January 21, 1997, a 37-yr-old man was admitted with severe (PaO2 = 59 mm Hg) PCP revealing HIV infection (Figure 1A). Chest radiograph showed diffuse granular opacities (Figure 2A). The CD4+ lymphocyte count was 7/mm3 and the plasma viral load 140,000 copies/ml. He improved on parenteral cotrimoxazole and methylprednisolone. On February 6, the PaO2 and chest radiograph were normal (Figure 2B); steroids were withdrawn, cotrimoxazole was given orally, and HAART (zidovudine, lamivudine, and indinavir) was introduced.
|
|
Eleven days later, he developed acute respiratory failure with high-grade fever. Chest radiograph examination disclosed patchy alveolar opacities in the two upper lobes (Figure 2C). The PaO2 was 69 mm Hg. Bronchoscopy with protected brushing, bronchoalveolar lavage (BAL), and bronchial and transbronchial biopsies were performed. Cytologic analysis of BAL fluid (BALF) showed 900,000 cells/ml, comprising 30% alveolar macrophages (0% siderophages), 59% lymphocytes, and 11% neutrophils. A few P. carinii cysts persisted, together with cytomegalovirus (CMV) inclusion cells. Microbiologic tests of respiratory, blood, and urinary specimens were negative, except for one blood sample and one BAL sample that yielded CMV. Bronchial and transbronchial biopsies showed no CMV inclusions in alveolar or endothelial cells. Other laboratory tests were normal. The CD4+ cell count was 38/mm3, and viral load was undetectable. Despite the absence of documented bacterial infection, the patient was treated with imipenem and amikacin with no improvement. Similarly, despite the absence of CMV retinitis or colitis, a 21-d course of foscavir was also given. On February 26, cotrimoxazole was continued at a prophylaxis dose and HAART was interrupted because of the elevation of serum transaminases. Surgical lung biopsy was performed on March 7 because of the persistence of fever and radiologic abnormalities, despite a partial improvement in respiratory function. Macroscopically, there was an inflammatory condensation of the right upper lobe. Histologic examination showed lesions of organizing pneumonia with alveolar necrosis and marked macrophage, neutrophil, lymphocyte, and plasma cell infiltration (Figures 3A through 3C). Almost all lung-infiltrating lymphocytes were of the T lineage as assessed by immunophenotyping (Figure 3D). By contrast to the low peripheral blood CD4/CD8 ratio (0.3), CD4 and CD8 lymphocyte subsets were equally represented in the lung tissue section (Figures 3E and 3F) There were no CMV inclusion cells. All tests for infectious agents were negative. The patient gradually became afebrile, and the X-ray films improved. HAART was reintroduced on March 9 with no further complications.
|
Case 2
On January 13, 1998, a 47-yr-old man was admitted with severe (PaO2 = 69 mm Hg) PCP revealing HIV infection (Figure 1B). The chest radiograph showed diffuse granular opacities. The CD4+ lymphocyte count was 28/mm3 and the plasma viral load 100,000 copies/ml. He received parenteral treatment with cotrimoxazole and methylprednisolone. On January 14, HAART was started with viramune, stavudine, and didanosine. On January 26, cotrimoxazole was stopped and replaced by aerosolized pentamidine because of a skin rash. His clinical and radiologic condition normalized, and steroids were stopped after 15 d of treatment.
Seventeen days after initiation of HAART he developed acute respiratory failure with high-grade fever. The chest radiograph showed diffuse alveolar opacities. He was intubated and mechanically ventilated. Bronchoscopy with protected brushing, BAL, and bronchial and transbronchial biopsies were performed. Cytologic analysis of BALF showed 990,000 cell/ml, with 10% alveolar macrophages, 80% lymphocytes, and 10% neutrophils. All tests for infectious agents in respiratory, blood, and urinary specimens were negative. Transbronchial biopsies showed an alveolar inflammatory infiltrate composed of lymphocytes, macrophages, and neutrophils, with a few persistent P. carinii cysts. Echocardiography was normal. Other laboratory tests were normal. The CD4+ lymphocyte count was 50/mm3 and the plasma viral load 33,000 copies/ml. Despite the absence of documented bacterial infection, the patient was treated with ceftriaxone, ofloxacin, and amikacin, without improvement. As the respiratory distress persisted and pulmonary pathologic findings showed a histologic pattern of organizing pneumonia in the absence of demonstrable infection, methylprednisolone was introduced, and HAART was interrupted. The patient gradually improved and was extubated on February 21. HAART was reintroduced with no further complications.
Case 3
On October 26, 1999, a 50-yr-old woman was admitted with severe PCP (PaO2 = 32 mm Hg) revealing HIV infection (Figure 1C). The chest X-ray film showed diffuse granular opacities. The CD4+ lymphocyte count was 230/mm3 and the plasma viral load 565,000 copies/ml. She received treatment with parenteral cotrimoxazole and methylprednisolone. A transient rash occurred but did not necessitate cotrimoxazole withdrawal. Her clinical condition improved. On November 12, 1999, the PaO2 and chest radiograph were normal. Methylprednisolone was withdrawn, cotrimoxazole was given orally, and HAART was introduced (zidovudine, lamivudine, and indinavir).
One week later, the patient developed acute respiratory failure with high-grade fever. The chest radiograph showed patchy alveolar opacities of the two upper lobes. The PaO2 was 50 mm Hg. Bronchoscopy with protected brushing, BAL, and bronchial and transbronchial biopsies were performed. Cytologic analysis of BALF showed 530,000 cell/ml, with 70% alveolar macrophages, 21% lymphocytes, 3% neutrophils, 6.5% eosinophils, and 0.5% basophils and a few persistent P. carinii cysts. All tests for infectious agents in respiratory, blood, and urinary specimens were negative. Bronchial and transbronchial biopsies showed an intense inflammatory infiltrate composed of lymphocytes, plasma cells, and macrophages. Despite the absence of documented bacterial infection, the patient was treated with ceftriaxone and ofloxacin, without improvement. Although there was no new cutaneous rash or hematologic, hepatic, or renal abnormalities, cotrimoxazole was replaced by atovaquone and aerosolized pentamidine, and steroids were reintroduced. On December 7, when the patient's clinical status had markedly improved, all medications except HAART were withdrawn. Cotrimoxazole was subsequently reintroduced with no adverse effects. The CD4+ lymphocyte count was 564/mm3 and the plasma viral load 1,386 copies/ml.
| |
DISCUSSION |
|---|
|
|
|---|
Between April 1996 and April 2000, 65 cases of PCP were diagnosed in our institution. The patients were treated with cotrimoxazole (or aerosolized pentamidine in case of documented allergy to sulfa drugs) for 21 d. Two-thirds of patients also required adjunctive steroid therapy because of mild to severe hypoxemia. In three cases, an acute respiratory failure after early introduction of HAART was observed. The three patients had very similar features. All had severe PCP revealing HIV infection, which completely resolved after 15 d of parenteral therapy combining cotrimoxazole and steroids. All subsequently developed acute respiratory failure with high-grade fever shortly after starting HAART (7 to 17 d), which was introduced early after the diagnosis of PCP (1 to 16 d). Lung pathologic findings and BAL showed a severe immune and inflammatory reaction associated with the persistence of rare P. carinii cysts. All the patients improved after discontinuation of HAART or steroid reintroduction, or both.
Cotrimoxazole-resistant PCP was improbable for several
reasons (3). First, the initial episode of PCP fully resolved after a 15-d course of cotrimoxazole. Second, these patients had
not previously received sulfa drugs
the main risk factor for
resistance to cotrimoxazole. Third, all the patients recovered,
whereas resistant PCP is usually fatal. Pulmonary superinfection was ruled out. No parasites, fungi, bacteria, or mycobacteria were found in any lung, blood, or urine samples, with the
exception of CMV in one patient. Moreover, broad-spectrum
antibiotic therapy, given despite the absence of documented
infection, did not lead to a clinical improvement. CMV detection in one blood and one BALF sample from Patient 1 was
not considered indicative of CMV pneumonia, as there was no
multiorgan CMV disease, anemia, or hemolytic syndrome, and
symptoms failed to resolve on anti-CMV therapy (4, 5). Furthermore, open-lung biopsy showed no histologic signs of CMV pneumonia. Drug-related pulmonary toxicity was ruled out
(6). The three patients had never previously received cotrimoxazole. In Case 1, cotrimoxazole was never discontinued,
and the patient recovered on this therapy. Patients 2 and 3 developed a skin rash related to cotrimoxazole toxicity. However, in Case 2, cotrimoxazole was stopped before onset of the
second episode of respiratory distress, and in Case 3, cotrimoxazole, discontinued during the second episode of respiratory
distress, was subsequently reintroduced with no recurrence of
respiratory symptoms. Finally, none of the HAART regimens
contained abacavir, which was recently implicated in cases of
acute respiratory distress syndrome and was pursued or reintroduced without relapse of pulmonary manifestation (7).
We conclude that the recurrence of acute respiratory failure resulted from an intense immune and inflammatory reaction after early HAART introduction and steroid withdrawal. Early steroid cessation may favor the relapse of steroid-controlled neutrophil alveolitis associated with PCP, resulting in a new episode of acute respiratory failure (8). Interestingly, this phenomenon has been described in patients in whom zidovudine was introduced during initial anti-PCP therapy (8). The improvement of neutrophil function observed during HAART may thus have contributed to the second episode of respiratory distress in our patients (9). Alternatively, it may have resulted from rapid pulmonary recruitment of fully competent immune cells responding to a few persistent P. carinii cysts acting as crude antigen. Paradoxical exacerbation of subclinical opportunistic infections such as viral hepatitis, CMV retinitis, and mycobacterial infection after HAART initiation has been well documented and might result from the rapid increase in competent antigen-specific memory T cells (10). Interestingly, studies of cellular immune reconstitution in animal models of PCP have shown similar paradoxical pulmonary inflammatory reactions (16). Severe combined immunodeficiency disease (SCID) mice with PCP developed acute respiratory failure related to a hyperinflammatory pulmonary reaction leading to P. carinii clearance after infusion of CD4+ cells (17). Histologic findings in these studies resembled those found in our patients, with an intense inflammatory infiltrate composed of lymphocytes, macrophages, and neutrophils, and a pattern of organizing pneumonia surrounding a few persistent P. carinii cysts. The efficacy of HAART in these patients was shown by the marked fall in plasma viral load. In contrast, circulating CD4+ cell counts did not increase in parallel, suggesting possible CD4+ cell sequestration in the lungs and their participation in the acute pulmonary reaction as also shown by the immunophenotyping of the lung tissue section from Case 1 (Figures 3D through 3F). This is supported by the observation that the reaction resolved after HAART discontinuation or steroid reintroduction, or both, as previously described in patients with paradoxical worsening of tuberculosis (11, 15).
These observations call for caution when introducing HAART early in patients with AIDS-inaugurating PCP, especially when adjunctive steroid therapy is indicated for mild to severe hypoxemia.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Pr. J. Cadranel, Service de Pneumologie et de Réanimation Respiratoire, Hôpital Tenon, 4 rue de la chine, 75020, Paris, France. E-mail: jacques.cadranel{at}tnn.ap-hop-paris.fr
(Received in original form July 11, 2000 and in revised form October 24, 2000).
| |
References |
|---|
|
|
|---|
1.
Wachter RM,
Luce JM.
Respiratory failure from severe Pneumocystis
carinii pneumonia: entering the third era.
Chest
1994;
106:
1313-1315
2. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998; 351: 228-230 [Medline].
3. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999; 354: 1347-1351 [Medline].
4. Herry I, Cadranel J, Antoine M, Meharzi J, Michelson S, Parrot A, Rozenbaum W, Mayaud C. Cytomegalovirus-induced alveolar hemorrhage in patients with AIDS: a new clinical entity? Clin Infect Dis 1996; 22: 616-620 [Medline].
5. Millar AB, Patou G, Miller RF, Grundy JE, Katz DR, Weller IV, Semple SI. Cytomegalovirus in the lungs of patients with AIDS: respiratory pathogen or passenger? Am Rev Respir Dis 1990; 141: 1474-1477 [Medline].
6. Silvestri RC, Jensen WA, Zibrak JD, Alexander RC, Rose RM. Pulmonary infiltrates and hypoxemia in patients with the acquired immunodeficiency syndrome re-exposed to trimethoprim-sulfamethoxazole. Am Rev Respir Dis 1987; 136: 1003-1004 [Medline].
7. Hetherington S, Steel H, Naderer O, Cutrell A, Powell W, Syres R. Hypersensitivity reactions during therapy with abacavir: analysis of 636 cases for clinical presentation and risk factors. In: Proceedings, 7th Conference of Retroviruses and Opportunistic Infections. San Francisco. 2000. Poster N60.
8.
Schiff MJ,
Farber BF,
Kaplan MH.
Steroids for Pneumocystis carinii
pneumonia and respiratory failure in the acquired immunodeficiency
syndrome: a reassessment.
Arch Intern Med
1990;
150:
1819-1821
9. Mastroianni CM, Lichtner M, Mengoni F, D'Agostino C, Forcina G, d'Ettorre G, Santopadre P, Vullo V. Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. AIDS 1999; 13: 883-890 [Medline].
10. McCormack JG. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infec Dis 1998; 26: 1008-1009 [Medline].
11.
Narita M,
Ashkin D,
Hollender ES,
Pitchenik AE.
Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with
AIDS.
Am J Respir Crit Care Med
1998;
158:
157-161
12. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, Japour AJ. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351: 252-255 [Medline].
13. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor [letter]. Lancet 1997; 349: 995-996 [Medline].
14. Jacobson MA, Zegans M, Pavan PR, O'Donnel JJ, Sattler F, Rao N, Owens S, Pollard R. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 350: 1443-1445 .
15. Furrer H, Malinverni R. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. Am J Med 1999; 106: 371-372 [Medline].
16. Roths JB, Marshall JD, Allen RD, Carlson GA, Sidman CL. 1990. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice: natural history and pathobiology. Am J Pathol 1990; 136: 1173-1186 [Abstract].
17. Roths JB, Sidman CL. 1992. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD+ T cells into severe combined immunodeficiency mice. J Clin Invest 1992; 90: 673-678 .
18. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, Harmsen AG. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999; 104: 1307-1317 [Medline].
This article has been cited by other articles:
![]() |
J W T Elston and H Thaker Immune reconstitution inflammatory syndrome Int J STD AIDS, April 1, 2009; 20(4): 221 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N. Atochina-Vasserman, A. J. Gow, H. Abramova, C.-J. Guo, Y. Tomer, A. M. Preston, J. M. Beck, and M. F. Beers Immune Reconstitution during Pneumocystis Lung Infection: Disruption of Surfactant Component Expression and Function by S-Nitrosylation J. Immunol., February 15, 2009; 182(4): 2277 - 2287. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Rosen Pulmonary Complications of HIV Infection ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 219 - 232. [Full Text] [PDF] |
||||
![]() |
J. Wang, F. Gigliotti, S. P. Bhagwat, S. B. Maggirwar, and T. W. Wright Pneumocystis stimulates MCP-1 production by alveolar epithelial cells through a JNK-dependent mechanism Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1495 - L1505. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Davaro and A. Thirumalai Life-Threatening Complications of HIV Infection J Intensive Care Med, March 1, 2007; 22(2): 73 - 81. [Abstract] [PDF] |
||||
![]() |
L. Huang, A. Morris, A. H. Limper, J. M. Beck, and on behalf of the ATS Pneumocystis Workshop Partici An Official ATS Workshop Summary: Recent Advances and Future Directions in Pneumocystis Pneumonia (PCP) Proceedings of the ATS, November 1, 2006; 3(8): 655 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
J-F. Cordier Cryptogenic organising pneumonia. Eur. Respir. J., August 1, 2006; 28(2): 422 - 446. [Abstract] [Full Text] [PDF] |
||||
![]() |
R F Miller, E Allen, A Copas, M Singer, and S G Edwards Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy Thorax, August 1, 2006; 61(8): 716 - 721. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Huang, A. Quartin, D. Jones, and D. V. Havlir Intensive care of patients with HIV infection. N. Engl. J. Med., July 13, 2006; 355(2): 173 - 181. [Full Text] [PDF] |
||||
![]() |
S. D. Swain, N. N. Meissner, and A. G. Harmsen CD8 T Cells Modulate CD4 T-Cell and Eosinophil-Mediated Pulmonary Pathology in Pneumocystis Pneumonia in B-Cell-Deficient Mice Am. J. Pathol., February 1, 2006; 168(2): 466 - 475. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Masur Management of Patients with HIV in the Intensive Care Unit. Proceedings of the ATS, January 1, 2006; 3(1): 96 - 102. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Rosen Intensive Care of Patients With Human Immunodeficiency Virus Infection: Time to Take Another Look J Intensive Care Med, December 1, 2005; 20(6): 312 - 315. [PDF] |
||||
![]() |
F. McAllister, C. Steele, M. Zheng, J. E. Shellito, and J. K. Kolls In Vitro Effector Activity of Pneumocystis murina-Specific T-Cytotoxic-1 CD8+ T Cells: Role of Granulocyte-Macrophage Colony-Stimulating Factor Infect. Immun., November 1, 2005; 73(11): 7450 - 7457. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Morris and L. Huang Intensive Care of Patients With HIV Infection: HAART Warming Improvement but Beware of Future HAART (and Heart) Attacks Chest, May 1, 2004; 125(5): 1602 - 1604. [Full Text] [PDF] |
||||
![]() |
T. D. Thullen, A. D. Ashbaugh, K. R. Daly, M. J. Linke, P. E. Steele, and P. D. Walzer Sensitized Splenocytes Result in Deleterious Cytokine Cascade and Hyperinflammatory Response in Rats with Pneumocystis Pneumonia despite the Presence of Corticosteroids Infect. Immun., February 1, 2004; 72(2): 757 - 765. [Abstract] [Full Text] [PDF] |
||||
![]() |
R J Boyton, D M Mitchell, and O M Kon The pulmonary physician in critical care * Illustrative case 5: HIV associated pneumonia Thorax, August 1, 2003; 58(8): 721 - 725. [Full Text] [PDF] |
||||
![]() |
New Considerations for PCP in the Era of Potent Combination Therapy: Sulfa Resistance and Immune Reconstitution AIDS Clinical Care, May 1, 2003; 2003(501): 10 - 10. [Full Text] |
||||
![]() |
S. Ruan, C. Tate, J. J. Lee, T. Ritter, J. K. Kolls, and J. E. Shellito Local Delivery of the Viral Interleukin-10 Gene Suppresses Tissue Inflammation in Murine Pneumocystis carinii Infection Infect. Immun., November 1, 2002; 70(11): 6107 - 6113. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. O'Neil The Changing Landscape of HIV-Related Lung Disease in the Era of Highly Active Antiretroviral Therapy Chest, September 1, 2002; 122(3): 768 - 771. [Full Text] [PDF] |
||||
![]() |
C. Mayaud, A. Parrot, and J. Cadranel Pyogenic bacterial lower respiratory tract infection in human immunodeficiency virus-infected patients Eur. Respir. J., July 1, 2002; 20(36_suppl): 28S - 39s. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Dean, D. I. Williams, D. R. Churchill, M. J. Fisher, M. Wislez, and J. Cadranel Transient clinical deterioration in hiv patients with Pneumocystis carinii Pneumonia after starting highly active antiretroviral therapy: Another case of immune restoration inflammatory syndrome Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1670 - 1670. [Full Text] [PDF] |
||||
![]() |
M. J. TOBIN Tuberculosis, Lung Infections, Interstitial Lung Disease, and Socioeconomic Issues in AJRCCM 2001 Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 631 - 641. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |